ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2025

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share

Potentially dilutive securities not included in the calculation of diluted loss per share are as follows (in thousands):

	AS OF MARCH 31,
	2025	2024
Outstanding stock options	3,422	1,511
Warrants to purchase common stock	141	12
Total	3,563	1,523

Schedule of Segment Reporting Information, by Segment

The table below summarizes the significant segment expenses which are regularly reported to and reviewed by the CODM for the purposes of making decisions regarding the allocation of resources and are reconciled to consolidated net loss for the three months ended March 31, 2025 and March 31, 2024 (in thousands):

	THREE MONTHS ENDED MARCH 31,
	2025		2024
Segment net loss
Research and development expense
Clinical trials	$	(13,265)	$	(19,778)
Personnel	(9,326)		(13,238)
Contract manufacturing	(8,550)		(25,202)
Equipment, depreciation, and facility	(2,583)		(1,920)
Other research and development	(3,153)		(3,713)
Total research and development expense	(36,877)		(63,851)
General and administrative expense
Personnel	(3,777)		(5,004)
Other general and administrative	(2,247)		(4,970)
Total general and administrative expense	(6,024)		(9,974)
Other expense	(410)		(4,885)
Segment and consolidated net loss	$	(43,311)	$	(78,710)